2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1311

A Multidisciplinary Cohort of Patients with Interstitial Pneumonia with Autoimmune Features
Abstract Number: 177

A Needs Assessment to Inform Rheumatology Curriculum Re-Design for Internal Medicine Residents
Abstract Number: 1427

A New Model of Care for Pediatric Rheumatology in Ontario: Preliminary Results from Pilot Telemedicine Clinics Utilizing Advanced Clinician Practitioners in Arthritis Care
Abstract Number: 2716

A New Score to Predict Digital Ulcers Combining Clinical Data, Imaging and Patient History in Systemic Sclerosis
Abstract Number: 380

A New Tool to Assess Muscle Strength in Polymyositis and Dermatomyositis: Hand-Held Dynamometry
Abstract Number: 954

A New Way to Think about Composite Magnetic Resonance Imaging Scores to Measure Osteoarthritis Severity and Progression
Abstract Number: 1343

A Novel Autoantibody Against DNA Damage Binding Protein-1 in Idiopathic Inflammatory Myopathy
Abstract Number: 2801

A Novel B-Cell-Helper IL-21-Producing CD8+ T Cell Subset Involved in the Pathogenesis of Rheumatoid Arthritis
Abstract Number: 918

A Novel Familial RELA Truncation Is Associated with Behçet’s-like Mucocutaneous Ulceration Syndrome
Abstract Number: 1027

A Novel IL-1 Mediated Autoinflammatory Disease Caused By a Specific Gain-of-Function Mutation in Dysferlin
Abstract Number: 1296

A Novel Potent and Selective Urate Transporter 1 Inhibitor, NC-2700, with pH-Raising Effect on Low Urinary pH
Abstract Number: 1299

A Novel Recombinant Oral Urate Oxidase (UrOx) Alln-346 Reduces Severe Hyperuricemia and Normalizes Hyperuricosuria in Nephropathic Urox Knockout (UrOxKO) Mice
Abstract Number: 676

A Novel Role for the Psoriatic Arthritis Impact of Disease Questionnaire
Abstract Number: 2009

A Novel Role of ZCCHC6 in the Regulation of MMP13 in Experimental Osteoarthritis in Mice
Abstract Number: 2342

A Pan-Canadian Study of Factors Associated with Perceived Doctor-Patient Communication in Patients with Systemic Lupus Erythematosus

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].